Paromomycin Targets HDAC1-mediated SUMOylation and IGF1R Translocation in Glioblastoma

Overview

Journal Front Pharmacol

Date 2024 Dec 26

PMID 39723246

Authors

Zhong Min

Yuejie Guo

Luo Ning

Affiliations

Soon will be listed here.

Abstract

Objective: This study investigates the effects of Paromomycin on SUMOylation-related pathways in glioblastoma (GBM), specifically targeting HDAC1 inhibition.

Methods: Using TCGA and GTEx datasets, we identified SUMOylation-related genes associated with GBM prognosis. Molecular docking analysis suggested Paromomycin as a potential HDAC1 inhibitor. assays on U-251MG GBM cells were performed to assess Paromomycin's effects on cell viability, SUMOylation gene expression, and IGF1R translocation using CCK8 assays, qRT-PCR, and immunofluorescence.

Results: Paromomycin treatment led to a dose-dependent reduction in GBM cell viability, colony formation, and migration. It modulated SUMO1 expression and decreased IGF1R nuclear translocation, an effect reversible by the HDAC1 inhibitor Trochostatin A (TSA), suggesting Paromomycin's involvement in SUMO1-regulated pathways.

Conclusion: This study highlights Paromomycin's potential as a therapeutic agent for GBM by targeting HDAC1-mediated SUMOylation pathways and influencing IGF1R translocation, warranting further investigation for its clinical application.

References

Nguyen H, Guz-Montgomery K, Lowe D, Saha D . Pathogenetic Features and Current Management of Glioblastoma. Cancers (Basel). 2021; 13(4). PMC: 7922739. DOI: 10.3390/cancers13040856. View

Dong F, Zheng L, Yang G . Construction of a TF-miRNA-mRNA Regulatory Network for Diabetic Nephropathy. Arch Esp Urol. 2024; 77(1):104-112. DOI: 10.56434/j.arch.esp.urol.20247701.14. View

Yan H, Parsons D, Jin G, McLendon R, Rasheed B, Yuan W . IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360(8):765-73. PMC: 2820383. DOI: 10.1056/NEJMoa0808710. View

Aldoghachi A, Aldoghachi A, Breyne K, Ling K, Cheah P . Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme. Neuroscience. 2022; 491:240-270. DOI: 10.1016/j.neuroscience.2022.03.030. View

Pechanova O . Why We Still Need Reliable Animal Models. Pathophysiology. 2022; 27(1):44-45. PMC: 8830462. DOI: 10.3390/pathophysiology27010006. View

Aly A, Singh P, Korytowsky B, Ling Y, Kale H, Dastani H . Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study. Neurooncol Pract. 2020; 7(2):164-175. PMC: 7318856. DOI: 10.1093/nop/npz042. View

Ciurea A, Mohan A, Covache-Busuioc R, Costin H, Glavan L, Corlatescu A . Unraveling Molecular and Genetic Insights into Neurodegenerative Diseases: Advances in Understanding Alzheimer's, Parkinson's, and Huntington's Diseases and Amyotrophic Lateral Sclerosis. Int J Mol Sci. 2023; 24(13). PMC: 10341997. DOI: 10.3390/ijms241310809. View

Sun Y, Luo Z, Chen Y, Lin J, Zhang Y, Qi B . si-Tgfbr1-loading liposomes inhibit shoulder capsule fibrosis via mimicking the protective function of exosomes from patients with adhesive capsulitis. Biomater Res. 2022; 26(1):39. PMC: 9389696. DOI: 10.1186/s40824-022-00286-2. View

Huang J, Lin W, Sun Y, Wang Q, He S, Han Z . Quercetin targets VCAM1 to prevent diabetic cerebrovascular endothelial cell injury. Front Aging Neurosci. 2022; 14:944195. PMC: 9475220. DOI: 10.3389/fnagi.2022.944195. View

10.

Cavill R, Jennen D, Kleinjans J, Briede J . Transcriptomic and metabolomic data integration. Brief Bioinform. 2015; 17(5):891-901. DOI: 10.1093/bib/bbv090. View

11.

Tian Y, Zhou Y, Chen F, Qian S, Hu X, Zhang B . Research progress in MCM family: Focus on the tumor treatment resistance. Biomed Pharmacother. 2024; 173:116408. DOI: 10.1016/j.biopha.2024.116408. View

12.

Abuaisheh A, Aboud O . Biogenic Amines in Gliomas: A Comprehensive Literature Review. Front Biosci (Landmark Ed). 2023; 28(7):141. DOI: 10.31083/j.fbl2807141. View

13.

Wu Z, Chen S, Wang Y, Li F, Xu H, Li M . Current perspectives and trend of computer-aided drug design: a review and bibliometric analysis. Int J Surg. 2024; 110(6):3848-3878. PMC: 11175770. DOI: 10.1097/JS9.0000000000001289. View

14.

Fareed A, Amir N, Ajaz H, Sohail A, Vaid R, Farhat S . Advances in BRAF-targeted therapies for non-small cell lung cancer: the promise of encorafenib and binimetinib. Int J Surg. 2024; 110(4):1891-1893. PMC: 11020025. DOI: 10.1097/JS9.0000000000001051. View

15.

Lo Cascio C, McNamara J, Melendez E, Lewis E, Dufault M, Sanai N . Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells. JCI Insight. 2021; 6(17). PMC: 8492336. DOI: 10.1172/jci.insight.149232. View

16.

Li S, Xie J, Chen Z, Yan J, Zhao Y, Cong Y . Key elements and checklist of shared decision-making conversation on life-sustaining treatment in emergency: a multispecialty study from China. World J Emerg Med. 2023; 14(5):380-385. PMC: 10613793. DOI: 10.5847/wjem.j.1920-8642.2023.076. View

17.

Zhang J, Zhang J, Huang X . Simultaneous Inversion of Particle Size Distribution, Thermal Accommodation Coefficient, and Temperature of In-Flame Soot Aggregates Using Laser-Induced Incandescence. Materials (Basel). 2024; 17(3). PMC: 11154289. DOI: 10.3390/ma17030634. View

18.

McGonigle P, Ruggeri B . Animal models of human disease: challenges in enabling translation. Biochem Pharmacol. 2013; 87(1):162-71. DOI: 10.1016/j.bcp.2013.08.006. View

19.

Tosakoon S, Lawrence W, Shiels M, Jackson S . Sex Differences in Cancer Incidence Rates by Race and Ethnicity: Results from the Surveillance, Epidemiology, and End Results (SEER) Registry (2000-2019). Cancers (Basel). 2024; 16(5). PMC: 10930733. DOI: 10.3390/cancers16050989. View

20.

Seto E, Yoshida M . Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014; 6(4):a018713. PMC: 3970420. DOI: 10.1101/cshperspect.a018713. View